WTX 124
Alternative Names: WTX-124Latest Information Update: 11 Sep 2026
At a glance
- Originator Werewolf Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 22 Apr 2026 Werewolf Therapeutics completes a phase I trial in Solid-tumours (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT05479812)
- 31 Dec 2025 Werewolf Therapeutics has patent protection covering IL-2 INDUKINE molecules and its WTX 124 product candidate in the US, Hong Kong, Japan, Mexico and Russia
- 18 Dec 2025 WTX 124 is available for licensing as of 18 Dec 2025. https://werewolftx.com/